prostate cancer
Researchers at the Keck School of Medicine of the University of Southern California (USC) have identified a novel genetic mechanism that may govern an individual's risk of developing prostate cancer.
DURHAM, N.C. -- A new look at a large database of prostate cancer patients shows that obesity plays no favorites when it comes to increasing the risk of recurrence after surgery: Being way overweight is equally bad for blacks and whites, say researchers at Duke University Medical Center.
Twice-yearly treatment with denosumab, a new targeted therapy to stop bone loss, increased bone density and prevented spinal fractures in men receiving androgen-deprivation therapy for prostate cancer.
Men diagnosed with prostate cancer have a number of treatments to choose from, but it's a daunting task to figure out the right mix of therapies for an individual patient.
HOUSTON - Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.
Ladies and Gentlemen! Head on over to Beyond The Short Coat for the Skeptics' Circle: your fortnightly romp through skeptical posts, be they about the Obama birth certificate conspiracy, the latest pseudoscientific concoction, or whatever else people need a dose of evidence-based evaluation about today. You may also find a link to my first ever post! A cup of skepticism about the promises of green tea for prostate cancer.
New Orleans, LA -- The latest findings of the North Carolina-Louisiana Prostate Cancer Project reveal potential new targets for reducing racial disparities in prostate cancer survival and highlight the importance of the health care delivery system.
Men who have a regular, ongoing relationship with a health care provider are more likely to receive prostate cancer screening and less likely to be diagnosed with advanced prostate cancer, regardless of their race, according to a University of North Carolina study published in the current issue of the journal Cancer.
Investigators at Memorial Sloan-Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.
BOSTON -- The androgen receptor -- a protein ignition switch for prostate cancer cell growth and division -- is a master of adaptability. When drug therapy deprives the receptor of androgen hormones, thereby halting cell proliferation, the receptor manages to find an alternate growth route.
Men with early stages of prostate cancer who delay radical treatment in favor of an approach of "expectant management" do not have high levels of anxiety and distress. That is the conclusion of a new study published in the September 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society.
COLUMBUS, Ohio -- A study led by researchers at the Ohio State University Comprehensive Cancer Center and Dana-Farber Cancer Institute reveals how late-stage, hormone-independent prostate tumors gain the ability to grow without need of hormones.
Researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered a new gene fusion that is highly expressed in a subset of prostate cancers. The results may lead to more accurate prostate cancer testing and new targets for potential treatments.
NEW YORK (July 8, 2009) -- A new finding reveals that African-American patients with breast, ovarian, and prostate cancer tend to die earlier than patients of other races with these cancers, even when they receive identical medical treatment and when socioeconomic factors are controlled for.
Nobody likes Mondays. Here is some cancer news to lift your mood.
